**Cistanche tubulosa** induces reactive oxygen species-mediated apoptosis of primary and metastatic human colon cancer cells

Afnan Saleh Al-Menhali¹, Safya Ali Jameela¹, Aishah A. Latiff³, Mohamed A. Elrayess², Mohammed Alsayrafi¹, Morana Jaganjac¹*  
¹Anti Doping Lab Qatar, Toxicology and Multipurpose, Doha, Qatar.  
²Anti Doping Lab Qatar, Life Science Research, Doha, Qatar.  
³Morana Jaganjac, PhD, Senior Scientist, Toxicology and Multipurpose, Labs, Anti Doping Lab Qatar, Sport City Road, Doha, Qatar. Phone: +97444132846; Fax: +97444132997

**ABSTRACT**

Colon cancer is the third most common cancer worldwide. Conventional therapies have shown moderate efficacy with severe adverse effects, therefore there is an urgent need for safer alternatives. In this study, *Cistanche tubulosa*, local name Thanoon, was considered as a potential phytotherapeutic strategy because of its known high therapeutic potential in traditional medicine and wide abundance in the Middle East region. Bioactive compounds were extracted from powdered *Cistanche tubulosa* and tested for their anticancer properties against four colon cancer cell lines including two derived from primary tumor (CaCo2 and HCT116) and two derived from metastatic site (LoVo and SW620). Effect of *Cistanche tubulosa* on induction of apoptosis and cellular redox homeostasis were also investigated. *Cistanche tubulosa* exhibited a concentration and time-dependent inhibition of proliferation of all tested cancer cell lines by more than 60% upon 72 hours treatment with 1 mg/mL of crude extract. Inhibition of proliferation was marked by induction of apoptosis, intracellular reactive oxygen species production and mitochondrial superoxides. This data suggest that *Cistanche tubulosa* is a promising candidate for additive anti-colon cancer therapy. This is the first study showing anticancer bioactivity of *Cistanche tubulosa* against colon cancer cells.

**Abbreviations:** 7-AAD, 7-Amino-Actinomycin D; CTE, *Cistanche tubulosa* extract; EMEM, Eagle's Minimum Essential Medium; FBS, fetal bovine serum; DCF, 2,7-dichlorofluorescein; DCFH-DA, 2,7-dichlorodihydrofluorescein diacetate; DMEM, Dulbecco’s Modified Eagle’s Medium; DMSO, dimethylsulfoxide; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium; PE, Phycoerythrin; RFU, relative fluorescence units; ROS, reactive oxygen species.

**INTRODUCTION**

Colorectal cancer is one of the most common cancers worldwide (Brenner et al., 2014), and its incidence is constantly increasing with an estimated 2.4 million cases in 2035, due to modern diet and lifestyle, along with reduced physical activity. Current efforts are not sufficient to combat the present epidemic of colorectal cancer and therefore novel approaches are needed for effective prevention and treatment including changes in lifestyle in combination with safer alternative interventions such as phytotherapeutics (Weidner et al., 2015). Phytotherapy, the use of medicinal plants to treat diseases, has been an inevitable part of ancient human history. Medicinal plants have long been utilized as alternative treatment sources for cancers, representing more than thirty percent of anticancer agents used in conventional medicine (Balunas and Kinghorn, 2005; Saibu et al., 2015). Some of the best known examples include extracts from *Catharanthus roseus* G. Don. (Apocynaceae), Taxus baccata L. (Taxaceae) and Camptotheca acuminate Decne (Nyssaceae) (Cragg and Newman, 2005; da Rocha et al., 2001). Several herbal extracts and phytochemicals were shown to exert antitumor effects in colorectal cancer attributed to the induction of reactive oxygen species (ROS) production and associated apoptosis of cancer cells as the case of extracts from *Melissa officinalis* (Weidner et al., 2015).

* Corresponding Author
Morana Jaganjac, PhD, Senior Scientist, Toxicology and Multipurpose Labs, Anti Doping Lab Qatar, Sport City Road, Doha, Qatar. Phone: +97444132846; Fax: +97444132997

© 2016 Pachacama Al-Menhal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License -NonCommercial-ShareAlikeUnported License (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Among phytotherapeutic candidates, *Cistanche tubulosa*, an Orobanchaceae parasitic desert plant (Jiang *et al*., 2009) that is widely distributed in arid and semi-arid regions of Africa, Asia and the Mediterranean region, has been shown to have valuable medicinal properties. *Cistanche tubulosa* has been extensively used in traditional medicine, and suggested to have curative effects in kidney deficiency, morbid leucorrhoea, metrorrhagia, female infertility, and senile constipation (Jiang *et al*., 2009). In addition to its traditional medicinal uses, important medicinal properties of *Cistanche Tubulosa* have been intensively studied during the last decade including vasorelaxant (Yoshikawa *et al*., 2006), hepatoprotective (Morikawa *et al*., 2010), anti-hyperglycemic and hypolipidemic effects (Xiong *et al*., 2013). *Cistanche Tubulosa* was also suggested as a potent enhancer of the immune system, promoter of bone formation, and an anti-aging and anti-fatigue agent (Xu *et al*., 2014). Furthermore, the *Cistanche tubulosa* extract has been shown to block amyloid deposition in Alzheimer’s disease model (Wu *et al*., 2015). Despite its various therapeutic uses, the effect of *Cistanche Tubulosa* as a potential anticancer agent has not been studied yet.

In the present work we have investigated the anticancer effect of *Cistanche Tubulosa* on two primary and two metastatic colon cancer cell lines and the potential mechanisms underlying this effect.

**MATERIALS AND METHODS**

**Collection and preparation of plant extract**

The samples of *Cistanche tubulosa* were collected from desert area in Qatar during 2014 and the authenticity of the plant was confirmed by herbariologist. Voucher samples are archived in the Toxicology and Multipurpose Department at ADLQ. The sun-dried plant samples were grinded with Retsch Knife Mill Grindomix GM300 into fine powder. Twenty grams of powder were extracted with 200 mL ultrapure water over night at 37 °C on a rotary shaker at 200 rpm. The crude *Cistanche tubulosa* extracts (CTE) were centrifuged for 30 min at 8000 rpm to pellet non-soluble compounds, supernatant collected and freeze dried using Labconco Freezone 6 plus Freeze dryer. The dried extract was reconstituted in Dulbecco’s Modified Eagle’s Medium (DMEM, SIGMA, Germany) to a concentration of 20 mg/mL and sterile filtered through 0.2 micron membrane filter.

**Cell lines and cell maintenance**

Human colon carcinoma cell lines CaCo2, SW620 and LoVo were obtained from Cell Lines Service (CLS, Eppelheim, Germany) while HCT 116 cell line was a kind gift from the Biological and Environmental Sciences, Department at Qatar University. CaCo2 and HCT11 were derived from the primary site of colon carcinoma while SW620 and LoVo derived from metastatic site. SW620, HCT116 and LoVo cells were cultured and maintained in DME Medium while CaCo2 cells were maintained in Eagle’s Minimum Essential Medium (EMEM, SIGMA, Germany). The cells were grown as monolayer cultured at 37°C in respective medium supplemented with 10% fetal bovine serum (FBS, SIGMA, Germany) and 1% Penicillin/Streptomycin (SIGMA, Germany) in a humidified atmosphere containing 5% carbon dioxide.

**Cell viability assay**

The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium (MTT) assay was used to evaluate the cytotoxic activity of CTE similarly as described earlier (Jaganjac *et al*., 2010). The seeding density of CaCo2, HCT116, SW620 and LoVo cells cultured in 96-well plates was 10⁴ cells per well. Cells were plated in respective medium supplemented with 10% FBS 24 hours prior to treatment. After 24 hours, the medium was removed and cells were treated with 0, 0.25, 0.5, 1 and 2 mg/mL of CTE for 24, 48 and 72 hours at 37°C in a humidified atmosphere containing 5% CO₂. Upon CTE treatment, the medium was removed and 40 μL of MTT solution (0.5 mg/mL) added to each well.

After 3 h of incubation, MTT solution was removed, the formazan product dissolved in dimethylsulfoxide (DMSO, SIGMA, Germany), and the absorbance measured at 590 nm with microplate reader (Infinite 200 PRO NanoQuant, Tecan Trading AG, Switzerland).

**Apoptosis assay**

Apoptosis in CaCo2, HCT116, SW620 and LoVo cells was detected using PE Annexin V Apoptosis Detection Kit I with 7-Amino-Actinomycin D (7-AAD) as a vital dye (Becton Dickinson International, Belgium) according to the manufacturer's instruction. Briefly, cells were seeded in 24-well plates at a density of 5x10⁴ cells/well in a respective media supplemented with 10% FBS for 24 h prior to the addition of CTE (0, 0.5 or 1 mg/mL). Following 24 CTE incubation, cells were harvested, washed twice with cold phosphate-buffered saline and stained with Phycoerythrin (PE) Annexin V and 7-AAD for 15 min at room temperature in the dark. Stained cells were analyzed within 1 hour by flow cytometry using FACS. Aria III flow cytometer and FACSDiva software (Becton Dickinson) at a slow flow rate with a minimum of 10⁴ cells. Treatment of cells for 4 hours with 6 μM camptothecin (SIGMA) was used as a positive control for the assay.

**Intracellular ROS production**

Intracellular ROS production was examined using 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA, SIGMA, Germany). DCFH-DA is a nonfluorescent probe, which is oxidized with intracellular ROS to the fluorescent compound 2,7-dichlorofluorescein (DCF) (Poljak-Blazi *et al*., 2011). The DCFH-DA assay was performed similarly as we have described before (Cindric *et al*, 2013; Poljak-Blazi *et al*., 2011). Briefly, the seeding density of CaCo2, HCT116, SW620 and LoVo cells cultured in 96-well black plates was 10⁴ cells per well. Cells were plated in respective medium supplemented with 10% FBS for 24 hours. Prior to treatment cells were incubated with 10 μM DCFH-DA at 37°C for 30 min in 5% CO₂ / 95% air. Cells were then washed and
treated with 0, 0.5 and 1 mg/mL of CTE in the medium w/o phenol red. The intracellular ROS formation was monitored continuously throughout 25 hours at 37°C and 5% CO₂ using microplate reader with top fluorescence and gas control module (Infinite 200 PRO, Tecan Trading AG, Switzerland). The fluorescence intensity was measured with an excitation wavelength of 500 nm and emission detection at 529 nm. The arbitrary units, relative fluorescence units (RFU), were based directly on fluorescence intensity.

Mitochondrial superoxide generation

The ability of CTE to induce superoxide generation by mitochondria was estimated using cell-permeable, mitochondria targeted MitoSOX Red probe (Life Technologies) and Hoechst 33342 for nuclear staining (Life Technologies). CaCo2, HCT116, SW620 and LoVo cells were seeded in 96-well plates at a density 10⁴ cells per well in a respective medium supplemented with 10% FBS for 24 hours. Cells were then loaded with 4 µM of MitoSOX and 2 µM of Hoechst 33342 for 20 min, excess dye washed and wells treated with 0, 0.5 and 1 mg/mL of CTE for 24 hours at 37°C and 5% CO₂. The fluorescence intensity was measured with an excitation wavelength of 510 nm and emission detection at 580 nm for MitoSOX and an excitation wavelength of 350 nm and emission detection at 461 nm for Hoechst 33342 using microplate reader with top fluorescence (Infinite 200 PRO, Tecan Trading AG, Switzerland).

Statistical analysis

Descriptive statistics were shown as the mean +/- SD. The significance of differences between groups was assessed using the Student t-test and Chi-square test. When more than two groups were compared, we used one sided ANOVA with appropriate post hoc testing. The SPSS 11.01 for Microsoft Windows were used. Differences with P less than 0.05 were considered statistically significant.

RESULTS

The effect of CTE on proliferation of human colon cancer cell lines is shown in Figure 1. All CTE concentrations tested showed a strong inhibitory effect on CaCo2 cell line in a concentration and time dependent manner (Figure 1A). Seventy two hours of CTE treatment inhibited the growth of CaCo2 cells by more than 60% compared to control (p < 0.05 for all concentrations). Significant impact of CTE treatment on HCT116 cell growth was also detected at all-time points at the two highest concentrations (1 mg/mL and 2 mg/mL), reaching greater than 70% reduction at latter concentration (Figure 1B, p < 0.05).

Although the two lower CTE concentrations (0.25 and 0.5 mg/mL) significantly reduced HCT116 growth of cells after 24 hours (p<0.05), they had no significant effect following 72 hours treatment compared to control (p>0.05). Time and concentration dependent inhibition of proliferation with CTE was further confirmed in LoVo cells by more than 60% at highest concentration (p < 0.05) (Figure 1C), and all four CTE concentrations tested reduced the growth of SW620 cells after 48 hours (Figure 1D, p < 0.05 for all). After 72 hours of treatment the same effect was observed only for the two highest concentrations (p < 0.05) while 0.25 and 0.5 mg/mL concentrations showed no significant effect compared to control (p > 0.05). The impact of 0.5 and 1 mg/mL CTE treatment on induction of apoptosis was further tested in all four cell lines (Figure 2). Increased number of cells in early apoptosis was detected in HCT116 and LoVo following 24 hours treatment with 0.5 mg/mL (p<0.05, Figure 2B and 2C) and in all cell lines at 1 mg/mL (p<0.05). Significant increase in necrotic or late apoptotic cell number was further observed in CaCo2 and SW620 cell lines (p<0.05, Figure 2A and 2D).

Ability of CTE to induce intracellular ROS production is demonstrated in Figure 3. Three hours following CTE treatment there was a strong increase in intracellular ROS production in all cell lines (p<0.05). The intracellular ROS production increased progressively throughout the 25 hours treatment in a time and concentration dependent manner. Furthermore, staining of cells with mitochondria targeted probe revealed a strong impact of CTE on mitochondrial superoxide production in a concentration dependent manner (Figure 4). Highest increase in superoxide production by mitochondria was observed in HCT116 (69%, Figure 4B) and LoVo cells (82%, Figure 4C) following 24 hours treatment with 1 mg/mL of CTE.
Fig. 1: Effect of *Cistanche tubulosa* on the viability of colon cancer cell lines. Cell viability measured by MTT assay of (A) CaCo2, (B) HCT116, (C) LoVo and (D) SW620 cells are presented as percentage of control untreated colon cancer cell line. Mean values (±SD) for 5-replicates of representative experiment is given: (*) significance p<0.05 in comparison to control untreated respective cells.

Fig. 2: *Cistanche tubulosa* water extract induces apoptosis in human colon cancer cells. Annexin-V-FITC flow cytometry analyses of (A) CaCo2, (B) HCT116, (C) LoVo and (D) SW620 cells are presented as percentage of control untreated colon cancer cell line. Mean values (±SD) for 3-replicates of representative experiment is given: (*) significance p<0.05 in comparison to control untreated respective cells.
Fig. 3: *Cistanche tubulosa* water extract induces intracellular ROS production in a time- and dose-dependent. ROS production measured by DCFH-DA assay in (A) CaCo2, (B) HCT116, (C) LoVo and (D) SW620 cells is presented as mean RFU values (±SD) for the respective 5-replicates of representative experiment. (*) Significance p<0.05 in comparison to control untreated colon cancer cells.

Fig. 4: *Cistanche tubulosa* water extract induces mitochondrial superoxide production in human colon cancer cells. Fluorescence intensity of mitochondria targeted MitoSOX Red probe in A) CaCo2, (B) HCT116, (C) LoVo and (D) SW620 cells are presented as percentage of control untreated colon cancer cell line. Mean values (±SD) for 5-replicates of representative experiment is given: (*) significance p<0.05 in comparison to control untreated colon cancer cells.
DISCUSSION

Although earlier studies have reported numerous medicinal properties of *Cistanche tubulosa*, this is the first report of its anti-proliferative effect in malignant cells. *Cistanche tubulosa* bioactive compounds extracted with water, a highly polar solvent, showed strong anticancer bioactivity. We have previously compared the efficiency of *Cistanche tubulosa* solubilized in water against other solvents such as methanol and ethyl acetate, but water extracts exhibited the most promising anticancer activities (data not shown).

We have demonstrated the ability of CTE at 1 mg/mL and 2 mg/mL to inhibit 60% of the growth of both primary and metastatic colon cancer cell lines, revealing a potential important role of *Cistanche tubulosa* as a colon cancer treatment. Compared to normal cells, cancer cells are generally characterized by a disturbance in redox homeostasis and a common strategy of current anticancer therapies is to increase cellular oxidative stress (Yang et al., 2013). Although physiologically low levels of ROS have important role as signaling molecules, the excessive ROS production can contribute to cancer instability and malignancy (Liou and Storz, 2010). Paradoxically, this imbalance in cellular redox homeostasis renders cancer cells more vulnerable to ROS-induced cell death (Jaganjac et al., 2008; Nogueira and Hay, 2013). The anti-proliferative effect of CTE reported in this study can be mediated by various extra- and intracellular mechanisms of known and unknown compounds within the extract, targeting multiple pathways that play essential roles in apoptosis. In order to differentiate between different modes of cell death, we investigated the potential mechanism responsible for the observed CTE-induced cytotoxicity.

Our data indicate that CTE increases intracellular ROS production and consequently ROS-induced cell death. Redox state of the cell also plays a crucial role in regulating apoptosis and mitochondrial electron transport chain is one of the major sites of cellular ROS generation (Trachootham et al., 2008). Furthermore, the intracellular ROS could cause cellular apoptosis via both mitochondria-dependent and independent pathways (Sinha et al., 2013). Indeed, our data also indicate that CTE induced phosphatidylserine externalization, a common effect in apoptosis, in both primary and metastatic cancer cell lines, suggesting that the mechanism of CTE induced death is mediated by apoptosis rather than necrosis. The activation of apoptosis in cancer cells is a corrective strategy and many anticancer drugs may exert apoptotic effects in cancer cells.

Compounds or extracts with pro-apoptotic activities in cancer cells are therefore potentially useful in anticancer drug research (Wong, 2011). In order to determine whether CTE induced pro-apoptotic effect is mediated by mitochondria-induced ROS mechanism, we measured superoxide production using mitochondria targeted fluorescent probe in CTE treated cells. Our data clearly shows that CTE stimulates mitochondrial superoxide production suggesting that *Cistanche tubulosa* anticancer activity is at least in part mediated through mitochondria induced ROS mechanism.

CONCLUSIONS

In conclusion, our data suggests that the water extract of desert plant *Cistanche tubulosa* may represent a promising candidate for anticancer approach in combination with other conventional therapies for prevention and treatment of colon cancer. We also demonstrate that the toxicity of the plant extract against cancer cells is mediated by increased intracellular ROS production and, at least in part, by mitochondrial-dependent apoptosis. Further studies are ongoing to isolate and characterize the individual biologically active constituents responsible for anticancer activity.

More research is needed to evaluate the potential use of this extract as an effective chemopreventive agent and to understand the mechanisms of action on colon cancer cells at the molecular level. Further preclinical and clinical studies are also needed to confirm the observed beneficial health effects of *Cistanche tubulosa* for cancer prevention.

ACKNOWLEDGEMENTS

Financial support and sponsorship: This study was supported by the Anti Doping Lab Qatar.

Conflict of Interests: The authors’ declare no conflict of interest.

REFERENCES


How to cite this article: